Episode Details

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.

Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.

In this we cover:

• The spark that led to the founding of Enara Bio

• Enara's platform EDAPT® and how it finds dark antigens in tumors.
• Where the field of T-Cell therapy for solid tumors is today.
• The importance of culture in early stage biotech, and how the company has been built around putting people first.
• The next major milestones for Enara Bio.